Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)

Åhlén, Jan; Ahuja, Nita; Albertsmeier, Markus; Al‐Refaie, Waddah B.; Andtbacka, Robert H.I.; Angele, Martin K.; Bagaria, Sanjay P.; Baldini, Elizabeth H.; Barretta, Francesco; Beasley, Georgia M.; Blay, Jean‐Yves; Blazer, Dan G.; Bonvalot, Sylvie; Burtenshaw, Sally M.; Callegaro, Dario; Canter, Robert J.; Cardona, Kenneth; Casali, Paolo; Catton, Charles; Choi, Yoon–La; Colombo, Chiara; Paoli, Antonino De; Tos, Angelo Paolo Dei; Delaney, Tom; Desai, Anant; Dickson, Brendan C.; Ducimitiere, Francoise; Eilber, Fritz C.; Eržen, Darja; Ja, Fernandez; Fiore, Marco; Fletcher, Christopher; Ford, Samuel J.; Frezza, Anna Maria; Gelderblom, A. J.; Gervais, Mai‐Kim; Gladdy, Rebecca A.; Gonzalez, Ricardo J.; Grignani, Giovanni; Grignol, Valerie; Gronchi, Alessandro; Gyorki, David E.; Haas, Rick L.; Hamilton, Trevor D.; Hartmann, Wolfgang; Hayes, Andrew; Henzler, Thomas; Hohenberger, Peter; Italiano, Antoîne; Jakob, Jens; Jones, Robin L.; Kane, John M.; Kasper, Bernd; Katz, Steven C.; Kirsch, David G.; Lahat, Guy; Lee, Kyo Won; Roland, Christina L.; MacNeill, Andrea; Maestro, Roberta; Maki, Robert G.; Mann, Gary N.; Méeus, Pierre; Messiou, Christina; Miah, Aisha; Miceli, Rosalba; Moreira, Augusto; Mullen, John; Wasif, Nabil; Nessim, Carolyne; Novak, Marko; Ripoll, Vicente Olivares; Palassini, Elena; Pasquali, Sandro; Patel, Shreyaskumar; Pennacchioli, Elisabetta; Pillarisetty, Venu G.; Pollock, Raphael E.; Purgina, Bibianna; Quagliuolo, Vittorio; Radaelli, Stefano; Rastrelli, Marco; Raut, Chandrajit P.; Renne, Salvatore Lorenzo; Ridgway, Paul F.; Rutkowski, Piotr; Sandrucci, Sergio; Sanfilippo, Roberta; Sargos, P.; Sbaraglia, Marta; Schrage, Yvonne; Sicklick, Jason K.; Smith, Myles; Stacchiotti, Silvia; Stoeckle, Eberhard; Strauß, D.; Joo, Kim Sung; Swallow, Carol J.; Tap, William D.; Tseng, William W.; Coevorden, Frits van; Graaf, Winette van der; Houdt, Winan J. van; Wagner, Andrew J.; Wardelmann, Eva; Zakotnik, Branko

doi:10.1093/annonc/mdy052

Cited by 58 publications

(30 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The variability of all subtypes of sarcomas are not well described due to the heterogeneity of the disease, with subtypes varying in biology, behavior, and treatment responses [3–6]. The complexity and rarity of sarcomas make them challenging to study as well as medically manage.…”

Section: Introductionmentioning

confidence: 99%

“…The complexity and rarity of sarcomas make them challenging to study as well as medically manage. This has driven the development of many long-term institutional, multi-institutional, and national databases that collect epidemiological and clinical data on sarcomas to better understand the disease processes [3–6]. This study utilizes a nationally representative cancer database, the Surveillance, Epidemiology and End Results (SEER), to study sarcomas in the US over 12 recent years and evaluate trends in epidemiology, management, and survival.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Sarcomas in the United States: Recent trends and a call for improved staging

et al. 2019

View full text Add to dashboard Cite

Background and objectives Sarcomas represent a heterogeneous group of tumors, and there is lack of data describing contemporary changes in patterns of care. We evaluated the epidemiology of sarcomas over 12 recent years Methods The Surveillance, Epidemiology and End Results (SEER) database was queried for sarcoma cases from 2002-2014. Patient, tumor and treatment factors, and trends over time were studied overall and by subtype. Univariable and multivariable logistic regression models and 5-year survival and cause-specific mortality (CSM) were summarized. Results There were 78,527 cases of sarcomas with an overall incidence of 7.1 cases per 100,000 people, increasing from 6.8 in 2002 to 7.7 in 2014. Sarcoma NOS(14.8%) and soft tissue(43.4%) were the most common histology and primary site, respectively. A majority of tumors were high-grade(33.6%) and >5 cm(51.3%). CSM was 28.6% and 5-year survival was 71.4%. Many patients had unknown-grade(42.2%), which associated with 2.6 times increased odds of no surgical intervention. Conclusions This comprehensive national study highlights important trends including increasing incidence, changing histologic types, and underestimation of true incidence. A large proportion of sarcomas are inadequately staged (unknown-grade 42.2%) with lack of appropriate surgical treatment. Our study highlights need for standardization of care for sarcomas.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Sarcomas in the United States: Recent trends and a call for improved staging

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Billingsley et al have advocated complete resection of the metastatic site as a positive prognosis factor for pulmonary metastasis from soft tissue sarcoma and a longer disease-free interval (>12 months) [4]. Moreover, the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG) has reported that complete resection of lung metastasis without adjuvant therapy is not an absolute contraindication and occasionally has prolonged survival in selected patients [14]. In the present case, no recurrence was observed after retroperitoneal tumor resection, therefore the upper lobectomy for early lung cancer was sequentially performed four months after the initial operation.…”

Section: Discussionmentioning

confidence: 99%

A case report of left lower lobe segmentectomy for pulmonary metastasis from retroperitoneal liposarcoma

Yoshida

Haisa

et al. 2019

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

show abstract

“…Approximately 20-50% of patients will develop metastasis from either bone or soft tissue sarcomas, presenting either as de novo or recurrent advanced disease [ 2 – 4 ]. Treatment of advanced, metastatic disease includes systemic therapy (such as chemotherapy, targeted therapy, and more recently immunotherapy), radiation therapy, ablation, and surgery [ 5 – 7 ]. Of the methods, surgical resection of metastasis (metastasectomy) is the accepted standard of care for a select cohort of sarcoma patients, as it is thought that, with careful clinical section, one can achieve long term relapse-free survival and potential cure [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Survival by histology among patients with bone and soft tissue sarcoma who undergo metastasectomy: protocol for a systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: Metastasectomy is performed on a select cohort of patients with advanced and/or recurrent bone and soft tissue sarcomas because of the potential for long term relapse free and overall survival associated with the procedure. However, the evidence supporting metastasectomy is difficult to summarize without a systematic examination of existing literature. The objective of this systematic review will be to examine survival among both adults and children with advanced and recurrent bone and STS who undergo metastasectomy. Methods: We designed and registered a study protocol for a systematic review and meta-analysis. We will include data from survival studies (e.g., randomized trials, cohort studies, routine case registries, and case control) conducted in children and adults with advanced and recurrent bone and soft tissue sarcoma who undergo metastasectomy. The primary outcome will be overall survival. Secondary outcomes will be 30-day post-operative mortality, recurrence-free survival, time off systemic therapy, and patient-reported outcomes including quality of life end points where available. Literature searches will be performed in multiple electronic databases including Ovid MEDLINE ® (1946 to present), Ovid EMBASE (1974 to present), Web of Science, and Cochrane Library. Grey literature will be identified through searching references, conference abstracts, Papers First, and Google Scholar. Two investigators will independently screen all citations, full-text articles, and abstract data. Full-text articles selected for analysis will be assessed for quality and risk of bias. If feasible, we will conduct a random effects meta-analysis. Estimates will be stratified according to histology comparing survival based on organ of metastasectomy. Additional analysis will be conducted to explore the potential sources of heterogeneity according to various patient, disease, and treatment characteristics (e.g., metastasis status, age, disease burden, and concomitant interventions). Discussion: This systematic review and meta-analysis will identify, evaluate, and integrate data on survival of metastasectomy of bone and soft tissue sarcoma by organ of metastasis. Our findings may have implications for clinicians, patients, and their families when considering selection for resection of oligometastatic disease in de novo, or recurrent bone and soft tissue sarcoma. Implications for future research will be identified to improve the outcomes of these complex patients.

show abstract

Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)

Cited by 58 publications

References 115 publications

Sarcomas in the United States: Recent trends and a call for improved staging

Sarcomas in the United States: Recent trends and a call for improved staging

A case report of left lower lobe segmentectomy for pulmonary metastasis from retroperitoneal liposarcoma

Survival by histology among patients with bone and soft tissue sarcoma who undergo metastasectomy: protocol for a systematic review and meta-analysis

Contact Info

Product

Resources

About